Document Type : original article
Authors
- Maryam Marefat 1
- Mohammad Ali Kiani 2
- Masoud Mahdavirashed 3
- Monavar Afzalagaie 4
- Saeed Mohammadi 1
- Hamidreza Kianifar 2
- Seyyed Ali Jafari 2
- Maryam Khalesi 5
1 Fellowship, Department of Pediatrics, Facility of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
2 Professor, Department of Pediatrics, Facility of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
3 Associate Professor, Department of Radiology, Facility of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
4 Assistant Professor , Department of Biological Statistics, Facility of Hygiene, Mashhad University of Medical Science, Mashhad, Iran.
5 Associate Professor , Department of Pediatrics, Facility of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
Abstract
Background: Portal hypertension, a complication of chronic liver disease in children, can lead to severe gastrointestinal bleeding and an increased need for hospitalization and endoscopic treatment, potentially resulting in death. Statins, known for their anti-inflammatory, antioxidant, and anti-fibrotic effects, are used in the treatment of many chronic diseases. This study aimed to investigate the effects of rosuvastatin on improving portal pressure and esophageal varices while reducing bleeding associated with these conditions in children with cirrhosis.
Methods: This randomized clinical trial was conducted in children with compensated liver cirrhosis at Akbar Children's Hospital in Mashhad, Iran, between March 2023 and November 2024. Initially, endoscopy and Doppler ultrasound were performed on 32 patients aged 7–17 years. The control group received standard treatments for portal hypertension, while the intervention group received rosuvastatin tablets in addition to standard treatments. After a 6-month period, Doppler ultrasound and control endoscopy were repeated. All clinical, laboratory, sonographic, and endoscopic data were analyzed by a statistician, and the results were reported.
Results: The study included 32 children with cirrhosis (16 in the control group and 16 in the intervention group). The number of cases showing a decrease in ultrasonographic parameters of portal hypertension (SA-RI and RRA-RI) was higher in the rosuvastatin group (p=0.14 and 0.37). The grades of esophageal varices decreased by 26.7% and 20% in the control and rosuvastatin groups, respectively (p=0.66). Esophageal variceal bleeding occurred in 13.3% of cases in the control group and in 25% of cases in the rosuvastatin group,with no statistically significant difference between the two groups (p=0.41).
Conclusion: Over the 6-month follow-up period, rosuvastatin did not demonstrate a beneficial effect in reducing portal hypertension and variceal bleeding in children with compensated liver cirrhosis.
Keywords
- Zhang C, Liu Y, Zhao H, Wang G. Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019. Hepatology International. 2024 Feb;18(1):238-53.
- Ma D, Liu X, Ai G, Pan W, Liu L, Huang Y, et al. The etiology and differential diagnosis of “autoimmune hepatitis-like liver disease” in children: a single-center retrospective study. Frontiers in Pediatrics. 2024 May 16;12:1377333.
- Peng L, Wu S, Zhou N, Zhu S, Liu Q, Li X. Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity. BMC pediatrics. 2021 Dec;21:1-8.
- Eldredge JA, Hardikar W. Current status and future directions of liver transplantation for metabolic liver disease in children. Pediatric Transplantation. 2024 Feb;28(1):e14625.
- Sahota AK, Shapiro WL, Newton KP, Kim ST, Chung J, Schwimmer JB. Incidence of nonalcoholic fatty liver disease in children: 2009–2018. Pediatrics. 2020 Dec 1;146(6).
- Norsa L, Nicastro E, Di Giorgio A, Lacaille F, D’Antiga L. Prevention and treatment of intestinal failure-associated liver disease in children. Nutrients. 2018 May 24;10(6):664.
- Aftab K, Khurshid A, Fayyaz A, Jabeen I. Causes of portal hypertension in children. The Professional Medical Journal. 2021 Sep 30;28(10):1489-94.
- Sooraj K, Shivani FN, Khan MH, Kumar RR, Bai S, Hussaini H, et al. Frequency of causes of portal hypertension in children. Cureus. 2022 Jun;14(6).
- Nishino K, Kawanaka M, Manabe N, Suehiro M, Kawamoto H, Haruma K. Portal hypertensive gastropathy in liver cirrhosis: Prevalence, natural history, and risk factors. Internal Medicine. 2022 Mar 1;61(5):605-13.
- Gratacós-Ginès J, Pose E. Review of the role of statins in cirrhosis and portal hypertension. Clinical liver disease. 2023 Aug 1;22(2):50-7.
- Sharpton SR, Loomba R. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC. Hepatology. 2023 Dec 1;78(6):1896-906.
- Moctezuma-Velazquez C, Abraldes JG. The role of statins in cirrhosis. Current Treatment Options in Gastroenterology. 2022 Sep;20(3):316-35.
- Sung S, Al-Karaghouli M, Kalainy S, Cabrera Garcia L, Abraldes JG. A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. BMC gastroenterology. 2021 Dec;21:1-3.
- Kreidieh M, Hamadi R, Alsheikh M, Al Moussawi H, Deeb L. Statin use in patients with chronic liver disease and cirrhosis: current evidence and future directions. Gastroenterology Research. 2022 Feb;15(1):1.
- Trebicka J. Statins in Compensated and Decompensated Cirrhosis: Approaching the Bedside. InPortal Hypertension VII: Proceedings of the 7th Baveno Consensus Workshop: Personalized Care in Portal Hypertension 2022 Oct 19 (pp. 263-279). Cham: Springer International Publishing.
- Agarwal R, Wisnu W. The effect of statin therapy on mortality in adult patients with liver cirrhosis: An evidence-based case report. Acta Medica Indonesiana. 2022 Jul 1;54(3):491.
- De Gaetano V, Pallozzi M, Cerrito L, Santopaolo F, Stella L, Gasbarrini A, et al. Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives. Cancers. 2024 Mar 31;16(7):1388.
- Guixé-Muntet S, Quesada-Vázquez S, Gracia-Sancho J. Pathophysiology and therapeutic options for cirrhotic portal hypertension. The Lancet Gastroenterology & Hepatology. 2024 Apr 17.
- Sheng JY, Meng ZF, Li Q, Yang YS. Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension. Hepatobiliary & Pancreatic Diseases International. 2024 Feb 1;23(1):4-13.
- Rodrigues SG, Mendoza YP, Bosch J. Investigational drugs in early clinical development for portal hypertension. Expert opinion on investigational drugs. 2022 Aug 3;31(8):825-42.
- Vijayaraghavan R, Jindal A, Arora V, Choudhary A, Kumar G, Sarin SK. Hemodynamic effects of adding simvastatin to carvedilol for primary prophylaxis of variceal bleeding: a randomized controlled trial. Official journal of the American College of Gastroenterology| ACG. 2020 May 1;115(5):729-37.
- Wani ZA, Mir MM, Lone SN, Khan AA, Rather MK. How long and how far? Response maintenance of simvastatin as an add-on rescue therapy to carvedilol non-responders in chronic liver disease associated portal hypertension. Asian Journal of Medical Sciences. 2022 Apr;13(4):1.
- Bishnu S, Ahammed SM, Sarkar A, Hembram J, Chatterjee S, Das K, et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. European journal of gastroenterology & hepatology. 2018 Jan 1;30(1):54-9.
- Pollo-Flores P, Soldan M, Santos UC, Kunz DG, Mattos DE, da Silva AC, et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Digestive and liver disease. 2015 Nov 1;47(11):957-63.
- Alsaeid M, Sung S, Bai W, Tam M, Wong YJ, Cortes J, et al. Heterogeneity of treatment response to beta-blockers in the treatment of portal hypertension: A systematic review. Hepatology Communications. 2024 Feb 1;8(2):e0321.
- Wan S, Huang C, Zhu X. Systematic review with a meta-analysis: clinical effects of statins on the reduction of portal hypertension and variceal haemorrhage in cirrhotic patients. BMJ open. 2019 Jul 1;9(7):e030038.
- Pfisterer N, Schwarz M, Schwarz C, Putre F, Ritt L, Riedl F, et al. Statins, metformin, and RAS inhibitors did not reduce variceal bleeding risk and mortality in a large, real-life cohort of patients with cirrhosis. Plos one. 2024 Jun 13;19(6):e0302811.
- Werida R, Khairat I, Khedr NF. Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia. Biomedicine & Pharmacotherapy. 2021 Mar 1;135:111179.
)